Company / EPS (Basic)
Bristol Myers Squibb EPS (Basic) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
$3.88
FY2025
5-year range
-$3.99 / $3.88
FY2021-FY2025
Trend
+30.6%
vs FY2024
Sector context
#15 of 208
Health Care
What the data says
Among 208 Health Care companies, Bristol Myers Squibb is in the top 7% for eps (basic). EPS (Basic) has fluctuated over the past 10 years, ranging from $-3.99 in FY2022 to $3.88 in FY2025.
Based on SEC 10-K filings.
3.88 in FY2025 with a 5-year CAGR of +5.2%. Top quartile in the Health Care sector.
Improved from $3.15 to $3.88 over the past 2 years.
Health Care sector context is included.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +5.2%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 208This company $3.88 Sector average -$0.88
▼
+541.3% above sector average
Key checks
Key Insights
- In FY2025, eps (basic) increased 30.6% year-over-year.
- Ranks #15 out of 208 companies in the Health Care sector.
- Lowest eps (basic) in the period was in FY2022.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.88 | +30.6% |
| FY2024 | $2.97 | -5.7% |
| FY2023 | $3.15 | +178.9% |
| FY2022 | -$3.99 | -297.5% |
| FY2021 | $2.02 | -32.9% |
| FY2020 | $3.01 | +393.4% |
| FY2019 | $0.61 | -77.2% |
| FY2018 | $2.67 | +184.0% |
| FY2017 | $0.94 | -22.3% |
| FY2016 | $1.21 | -22.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026